OpenLB
Open Library of Bioscience
Advanced Search
Journal of bone and mineral metabolism
Jul, 2013;31 (4): 367-80.

Osteoporosis and treatments in Japan: management for preventing subsequent fractures.

Shuko Nojiri, Russel T Burge, Jennifer A Flynn, Shonda A Foster, Hideaki Sowa
Author Information
  1. Shuko Nojiri: Japan Health Technology Assessment, Eli Lilly Japan K.K., Sannomiya Plaza Building, 7-1-5, Isogamidori, Chuo-ku, Kobe, 651-0086, Japan. nojiri_shuko@lilly.com
PMID: 23536192 DOI: 10.1007/s00774-013-0444-y

Abstract

Prevalent fractures are major contributors to an increased risk of subsequent fractures, particularly in people with osteoporosis. While many studies have been conducted to assess the incidence of fracture in Japanese people with osteoporosis, far fewer have been conducted to assess the risk of subsequent fractures. This article reviews the morbidity, mortality, and risk of fracture in patients who are at high risk of subsequent fracture in Japan and the current treatment options available for these patients. Osteoporotic fractures in Japan are associated with high morbidity and mortality that result in significant financial and social costs. The rise in the proportion of elderly women in the Japanese population is contributing to a greater proportion of people with osteoporotic fractures and the high cost of osteoporosis. Although hip fractures have a significant effect on costs, a greater proportion of the Japanese population experience vertebral fractures. An increase in the incidence of vertebral fractures is concerning because preexisting vertebral fractures in older patients are associated with an increased risk of subsequent fractures. Hence, there is a clear rationale for pharmacological treatment of patients with prevalent vertebral fractures, or for those who are hospitalized or undergo surgery for osteoporotic fractures. Several pharmacological therapies are now available in Japan for the treatment of patients with osteoporosis. Understanding the consequences of subsequent fractures and the treatment options available for patients at high risk of subsequent fractures may contribute to clinical decision-making and improved outcomes for patients with osteoporosis.

References

J Bone Miner Res. 2000 Apr;15(4):721-39 [PMID: 10780864]
Drugs Aging. 2012 Mar 1;29(3):191-203 [PMID: 22372723]
Osteoporos Int. 2010 Jan;21(1):71-9 [PMID: 19499274]
J Bone Miner Metab. 2008;26(4):373-8 [PMID: 18600404]
Osteoporos Int. 2004 Nov;15(11):897-902 [PMID: 15490120]
Osteoporos Int. 2012 Apr;23(4):1381-90 [PMID: 21927926]
Osteoporos Int. 2003 Dec;14(12):1007-12 [PMID: 14557854]
Osteoporos Int. 2006 Feb;17(2):313-6 [PMID: 16217588]
Curr Med Res Opin. 2011 Jun;27(6):1273-84 [PMID: 21554143]
J Bone Miner Res. 2002 Jul;17(7):1237-44 [PMID: 12096837]
Lancet. 2009 Oct 3;374(9696):1196-208 [PMID: 19801098]
Int J Epidemiol. 1995 Dec;24(6):1171-7 [PMID: 8824859]
J Bone Miner Res. 1997 Jul;12(7):998-1004 [PMID: 9199997]
N Engl J Med. 2001 May 10;344(19):1434-41 [PMID: 11346808]
JAMA. 1999 Aug 18;282(7):637-45 [PMID: 10517716]
Yonsei Med J. 2008 Feb 29;49(1):119-28 [PMID: 18306478]
J Bone Miner Metab. 2010;28(1):55-9 [PMID: 19582539]
Osteoporos Int. 2009 Aug;20(8):1429-37 [PMID: 19101754]
Osteoporos Int. 2002 Dec;13(12):971-9 [PMID: 12459940]
J Bone Miner Metab. 2008;26(1):34-41 [PMID: 18095061]
J Bone Miner Res. 2009 Jun;24(6):1095-102 [PMID: 19113931]
Osteoporos Int. 2009 May;20(5):695-702 [PMID: 18836672]
Osteoporos Int. 2009 Apr;20(4):543-8 [PMID: 18633667]
Arch Osteoporos. 2009 Dec;4(1-2):71-77 [PMID: 20234789]
Bone. 2010 Sep;47(3):493-502 [PMID: 20580870]
Osteoporos Int. 2005 Oct;16(10):1239-46 [PMID: 15729479]
J Bone Miner Res. 2003 Aug;18(8):1547-53 [PMID: 12929946]
Obstet Gynecol. 2004 Oct;104(4):837-44 [PMID: 15458908]
Arthritis Rheum. 2002 Dec 15;47(6):651-4 [PMID: 12522840]
Osteoporos Int. 2002 Sep;13(9):723-30 [PMID: 12195536]
Curr Rheumatol Rep. 2003 Feb;5(1):65-74 [PMID: 12590887]
Osteoporos Int. 2009 Sep;20(9):1613-20 [PMID: 19137351]
J Clin Endocrinol Metab. 2002 Aug;87(8):3609-17 [PMID: 12161484]
Intern Med. 2011;50(5):397-404 [PMID: 21372448]
J Bone Miner Res. 2008 Dec;23(12):1923-34 [PMID: 18665787]
J Bone Miner Metab. 2006;24(2):100-4 [PMID: 16502115]
J Bone Miner Metab. 2009;27(5):620-8 [PMID: 19568689]
J Bone Miner Res. 2008 Apr;23(4):525-35 [PMID: 18072873]
Bone. 2007 Jun;40(6):1447-52 [PMID: 17045858]
J Orthop Sci. 2010 Nov;15(6):737-45 [PMID: 21116890]
Disabil Rehabil. 2010;32(10):826-35 [PMID: 19817664]
Toxicol Pathol. 2002 May-Jun;30(3):312-21 [PMID: 12051548]
J Bone Miner Res. 2005 Sep;20(9):1514-24 [PMID: 16059623]
Bone. 2003 Jan;32(1):78-85 [PMID: 12584039]
J Bone Miner Res. 2012 Dec;27(12):2429-37 [PMID: 22991313]
J Bone Miner Res. 2007 Feb;22(2):334 [PMID: 17129179]
J Bone Miner Metab. 2011 May;29(3):309-14 [PMID: 20814705]
J Bone Miner Res. 2010 Nov;25(11):2267-94 [PMID: 20842676]
Osteoporos Int. 2007 May;18(5):585-91 [PMID: 17146592]
Bone. 2004 Aug;35(2):375-82 [PMID: 15268886]
Osteoporos Int. 2006;17(7):986-95 [PMID: 16552468]
J Orthop Sci. 2006 Oct;11(5):446-9 [PMID: 17013730]
Mod Rheumatol. 2008;18(2):170-6 [PMID: 18297237]
Nihon Rinsho. 1998 Jun;56(6):1563-8 [PMID: 9648482]
Osteoporos Int. 2010 May;21(5):797-803 [PMID: 19618096]
J Pharmacol Exp Ther. 2000 Nov;295(2):431-7 [PMID: 11046073]
Bone. 2011 Sep;49(3):493-8 [PMID: 21605715]
J Bone Miner Res. 2011 Mar;26(3):519-29 [PMID: 20839291]
Osteoporos Int. 2009 Feb;20(2):187-95 [PMID: 19096746]
J Orthop Sci. 2006 Mar;11(2):127-34 [PMID: 16568383]
Bone. 2009 Jan;44(1):168-72 [PMID: 19010116]
Bone. 2010 Dec;47(6):1064-70 [PMID: 20832514]
J Craniomaxillofac Surg. 2011 Jun;39(4):272-7 [PMID: 20580566]
Osteoporos Int. 2011 Jan;22(1):97-103 [PMID: 20333358]
J Orthop Surg (Hong Kong). 2010 Aug;18(2):148-52 [PMID: 20808003]
Clin Calcium. 2004 Mar;14(3):371-6 [PMID: 15576994]
Jpn J Nurs Sci. 2010 Jun;7(1):96-107 [PMID: 20618681]
Endocr J. 2011;58(8):613-24 [PMID: 21778617]
J Bone Miner Metab. 2004;22(5):469-78 [PMID: 15316868]
Curr Med Res Opin. 2009 Apr;25(4):921-8 [PMID: 19250060]
Osteoporos Int. 2007 Oct;18(10):1397-403 [PMID: 17460805]
J Bone Miner Res. 1993 Jul;8(7):861-9 [PMID: 8352068]
BMC Fam Pract. 2006 May 09;7:31 [PMID: 16684358]
Osteoporos Int. 2003 Oct;14(10):793-800 [PMID: 12955333]
J Bone Miner Metab. 2002;20(5):311-8 [PMID: 12203038]
Arch Intern Med. 2003 Sep 22;163(17):2052-7 [PMID: 14504118]
Osteoporos Int. 2010 Sep;21(9):1513-22 [PMID: 19924494]
Bone. 2009 Jun;44(6):1078-84 [PMID: 19264155]
J Bone Miner Res. 2005 Sep;20(9):1507-13 [PMID: 16059622]
Clin Rheumatol. 2011 Aug;30(8):1105-11 [PMID: 21484222]
J Orthop Sci. 2010 Mar;15(2):192-7 [PMID: 20358331]
Calcif Tissue Int. 2012 Jan;90(1):14-21 [PMID: 22076525]
Osteoporos Int. 2010 Jun;21(6):1041-5 [PMID: 19597911]
Osteoporos Int. 2004 Jul;15(7):560-6 [PMID: 15067499]
Bone. 2011 Sep;49(3):520-5 [PMID: 21652001]
J Bone Miner Metab. 2010;28(1):68-76 [PMID: 19633810]
J Bone Miner Metab. 2010 Mar;28(2):233-9 [PMID: 19806302]

MeSH Term

Fractures, Bone
Humans
Incidence
Japan
Osteoporosis
Risk Factors
Journal Article Research Support, Non-U.S. Gov't Review

Word Cloud

Similar Articles

Cited By